Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Inc., Sanofi Genzyme, and Seagen Inc.

PER® Postgame™: Reporting the Latest Global Updates Across the Treatment of Breast Cancer

Release Date: December 8, 2021
Expiration Date: December 8, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in the treatment of breast cancer. In this educational program, these experts provide a comprehensive overview of noteworthy data presented at recent international society meetings held virtually in 2021. Topics include updates in breast cancer pathology and biomarkers, hormone receptor–positive (HR+), HER2-positive, and triple-negative breast cancers.

This educational activity is an archive of the live virtual webcast held on November 16, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Inc., Sanofi Genzyme, and Seagen Inc.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical, radiation, and surgical oncologists interested in the treatment of breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Assess emerging data for risk stratification and genomic testing to guide treatment planning for patients with breast cancer
Evaluate recently reported safety and efficacy data on emerging treatment strategies in breast cancer
Identify key patient eligibility criteria for recent and ongoing clinical trials and the relevance of these to treatment selection for patients with breast cancer
Determine the clinical implications of recently reported data for treatment paradigms in breast cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

Chair

Javier Cortés, MD, PhD
Head, International Breast Cancer Center (IBCC)
Barcelona, Spain
Clinical Investigator, Breast Cancer Research Program
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Disclosures: Grant research support: Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F.Hoffman-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma, Queen Mary University of London; Consultant: Roche, Celgene, Cellestia, AstraZeneca, Seagen, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses Pharma, HiberCell, BioInvent, GEMoaB, Gilead, Menarini, Zymeworks; Stock/Shareholder: MEDSIR; Other: Honoraria: Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme, Daiichi-Sankyo.

Faculty

Aditya Bardia, MD, MPH
Director, Breast Cancer Research Program
Associate Professor, Harvard Medical School
Attending Physician, Medical Oncology, Massachusetts General Hospital
Boston, MA

Disclosures: Grant research support: Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Daiichi Sankyo, AstraZeneca, Natera; Consultant: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Daiichi-Sankyo/AstraZeneca, Puma, Biotheranostics, Phillips, Eli Lilly and Company, Foundation Medicine.

Giuseppe Curigliano, MD, PhD
Professor of Medical Oncology at the University of Milan
Director, Division of Early Drug Development
European Institute of Oncology
Milano, Italy

Disclosures: Grant research support: Merck; Consultant: Bristol Myers Squibb, Pfizer, Roche, Lilly, Novartis, AstraZeneca, Seagen, Daichii Sankyo; Speakers’ Bureau: Lilly, Pfizer. Speakers’ bureau: Lilly, Pfizer.

Sara A. Hurvitz, MD, FACP
Professor of Medicine
Director, Breast Cancer Clinical Trials Program
Division of Hematology-Oncology
David Geffen School of Medicine
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
University of California
Los Angeles, CA

Disclosures: Consultant: Ambrx, Amgen, Arvinas, Bayer, Daiichi-Sankyo, Dignitana, Genentech, GSK, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Pieris Pharmaceuticals, Puma, Radius Health, Roche, Sanofi, Seagen; Stock/Shareholder: NKMAX; Other Support: Travel: Lilly.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.